Hao Liu

US Patent:

7173005, Feb 6, 2007

Filed:

Sep 24, 2002

Appl. No.:

10/253493

Inventors:

Renuka Pillutla - Bridgewater NJ, US
Olga Dedova - Highland Park NJ, US
Arthur J. Blume - East Greenwich RI, US
Neil I. Goldstein - Maplewood NJ, US
Renee Brissette - Clarksburg NJ, US
Pinger Wang - North Brunswick NJ, US
Hao Liu - Pennington NJ, US
Michael Lennick - Exton PA, US
Paul Fletcher - Cheshire CT, US

Assignee:

Antyra Inc. - Edison NJ
Novo Nordisk A/S - Bagsvaerd

International Classification:

C07K 7/06
A61K 38/17

US Classification:

514 12, 514 2, 514 3, 514 17, 530300, 530330

Abstract:

Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonist peptides may also be developed as therapeutics.

US Patent:

7863465, Jan 4, 2011

Filed:

Mar 29, 2007

Appl. No.:

11/727927

Inventors:

James M. Balkovec - Martinsville NJ, US
Frances Aileen Bouffard - Scotch Plains NJ, US
Bruno Tse - San Diego CA, US
James Dropinski - Colts Neck NJ, US
Dongfang Meng - Westfield NJ, US
Mark L. Greenlee - Plainfield NJ, US
Michael Peel - Chapel Hill NC, US
Weiming Fan - Chapel Hill NC, US
Ahmed Mamai - Raleigh NC, US
Hao Liu - Raleigh NC, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
Scynexis, Inc. - Research Triangle Park NC

International Classification:

C07D 311/00
C07D 315/00

US Classification:

549381, 417432

Abstract:

The present invention relates to novel enfumafungin derivatives of formula I and pharmaceutically acceptable salts thereof, their synthesis, and their use as inhibitors of (1,3)-β-D-glucan synthase. The present compounds and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising the present compounds and pharmaceutically acceptable salts thereof, are useful for treating or preventing antifungal infections and associated diseases and conditions.

US Patent:

20070004634, Jan 4, 2007

Filed:

Apr 24, 2006

Appl. No.:

11/410222

Inventors:

Renuka Pillutla - Bridgewater NJ, US
Olga Dedova - Highland Park NJ, US
Arthur Blume - East Greenwich RI, US
Neil Goldstein - Maplewood NJ, US
Renee Brissette - Clarksburg NJ, US
Pinger Wang - North Brunswick NJ, US
Hao Liu - Pennington NJ, US
Michael Lennick - Exton PA, US
Paul Fletcher - Cheshire CT, US

Assignee:

Novo Nordisk A/S - Bagsvaerd
Antyra Inc. - Edison NJ

International Classification:

A61K 38/08

US Classification:

514017000

Abstract:

Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonist peptides may also be developed as therapeutics.

US Patent:

20090053807, Feb 26, 2009

Filed:

Dec 3, 2007

Appl. No.:

11/949153

Inventors:

Renuka Pillutla - Bridgewater NJ, US
Olga Dedova - Highland Park NJ, US
Arthur J. Blume - East Greenwich RI, US
Neil I. Goldstein - Maplewood NJ, US
Renee Brissette - Clarksburg NJ, US
Pinger Wang - North Brunswick NJ, US
Hao Liu - Pennington NJ, US
Michael Lennick - Exton PA, US
Paul Fletcher - Cheshire CT, US

Assignee:

Novo Nordisk A/S - Bagsvaerd
Antyra Inc. - Edison NJ

International Classification:

C12N 5/06

US Classification:

435375

Abstract:

Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonist peptides may also be developed as therapeutics.

US Patent:

20210381819, Dec 9, 2021

Filed:

Nov 6, 2019

Appl. No.:

17/287061

Inventors:

- Oakland CA, US
Chee Wei Wong - Los Angeles CA, US
Hao Liu - Los Angeles CA, US
Jinghui Yang - Los Angeles CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

G01B 9/02
G02F 1/365
H01S 3/067
G01S 17/36
G01S 7/484

Abstract:

Systems and methods for soliton microcomb-based precision dimensional metrology via spectrally-resolved interferometry are described. In an embodiment, the system includes a dual-pumped soliton microcomb generator comprising a pump, a microresonator, and an auxiliary pump and that generates a single-soliton microcomb, an erbium-doped fiber amplifier that amplifies a C-band section of the soliton microcomb and a non-polarizing beam splitter that divides the soliton microcomb pulses into a reference arm pulse and a measurement arm pulse for an interferometer and recombines the reference arm pulse and the measurement arm pulse into a recombined beam upon their return.

US Patent:

20150144506, May 28, 2015

Filed:

Mar 15, 2013

Appl. No.:

14/401343

Inventors:

- Scottsdale AZ, US
Peiming Zhang - Gilbert AZ, US
Hao Liu - Tempe AZ, US

Assignee:

ARIZONA BOARD OF REGENTS on behalf of ARIZONA STATE UNIVERSITY - Scottsdale AZ

International Classification:

G01N 27/26

US Classification:

205782, 204400, 204406

Abstract:

Embodiments of the present disclosure are directed to recognition tunneling methods, systems and devices for the detection of carbohydrates by measuring tunneling currents of sugars which give distinct electronic signals in a tunnel gap functionalized respectively with, for example, in some embodiments, 4(5)-(2-mercaptoethyl)-1H imideazole-2-carboxamide and 4-mercaptophenylboronic acid molecules on at least one, and preferably each electrode.